1,678 results on '"Van Laere, Koen"'
Search Results
102. The impact of reconstruction and scanner characterisation on the diagnostic capability of a normal database for [123I]FP-CIT SPECT imaging
103. SDI-118, a novel procognitive SV2A modulator: First-in-human randomized controlled trial including PET/fMRI assessment of target engagement
104. Longitudinal Synaptic Density PET with 11C‐UCB‐J 6 Months After Ischemic Stroke
105. In Vivo Detection of Neurofibrillary Tangles by 18F-MK-6240 PET/MR in Patients With Ischemic Stroke
106. Intra-individual qualitative and quantitative comparison of [68Ga]Ga-DOTATATE PET/CT and PET/MRI
107. Development, initial validation, and application of a visual read method for [18F]MK‐6240 tau PET
108. Additional file 1 of Longitudinal APOE4- and amyloid-dependent changes in the blood transcriptome in cognitively intact older adults
109. Development, initial validation, and application of a visual read method for [ 18 F]MK‐6240 tau PET
110. Additional file 2 of Longitudinal APOE4- and amyloid-dependent changes in the blood transcriptome in cognitively intact older adults
111. Prospective comparison of [¹⁸F]AlF-NOTA-octreotide PET/MRI to [⁶⁸Ga]Ga-DOTATATE PET/CT in neuroendocrine tumor patients
112. MRI/PET Brain Imaging
113. PET Quantification in Neuropsychiatry
114. Applications of Small-Animal Imaging in Neurology and Psychiatry
115. Al18F-NOTA-octreotide: first comparison with 68Ga-DOTATATE in a neuroendocrine tumour patient
116. PET imaging of TSPO in a rat model of local neuroinflammation induced by intracerebral injection of lipopolysaccharide
117. Identifying a glucose metabolic brain pattern in an adeno-associated viral vector based rat model for Parkinson’s disease using 18F-FDG PET imaging
118. Volume-of-interest-based supervised cluster analysis for pseudo-reference region selection in [18F]DPA-714 PET imaging of the rat brain
119. Retention of [18F]fluoride on reversed phase HPLC columns
120. Longitudinal follow-up and characterization of a robust rat model for Parkinson's disease based on overexpression of alpha-synuclein with adeno-associated viral vectors
121. The novel M4 PAM PET tracer [11C] MK‐6884: a novel biomarker for measuring target engagement of muscarinic M4 positive allosteric modulators (PAMs) as well as cholinergic tone in patients with Alzheimer’s disease
122. Weighted Gene Co‐Expression Network Analysis for peripheral whole‐blood RNA sequencing in asymptomatic Alzheimer’s disease
123. 18 F‐MK6240 tau in ento‐ and perihinal cortex is related to episodic memory in the earliest stages of Alzheimer’s disease
124. Predictive value of a plasma p‐tau181‐specific assay for amyloid accumulation in asymptomatic Alzheimer’s Disease
125. [18F] MFBG PET imaging: biodistribution, pharmacokinetics, and comparison with [123I] MIBG in neural crest tumour patients
126. Cerebral glucose changes after chemotherapy and their relation to long-term cognitive complaints and fatigue
127. Positron emission tomography in amyotrophic lateral sclerosis: Towards targeting of molecular pathological hallmarks
128. Increased Cerebral Cannabinoid-1 Receptor Availability Is a Stable Feature of Functional Dyspepsia : A [¹⁸F]MK-9470 PET Study
129. Decreased in vivo availability of the cannabinoid type 2 receptor in Alzheimer’s disease
130. SPECT and PET
131. Early decrease of type 1 cannabinoid receptor binding and phosphodiesterase 10A activity in vivo in R6/2 Huntington mice
132. Clinical SPECT and PET for Management of Patients with Refractory Epilepsy
133. Brain Tumor Imaging: European Association of Nuclear Medicine Procedure Guidelines
134. Diagnostic accuracy and validation of 18F-fluorodeoxyglucose positron emission tomography scores in a large cohort of patients with polymyalgia rheumatica
135. Longitudinal Positron Emission Tomography Imaging of Presynaptic Terminals in Early Parkinson's Disease
136. Single Photon Emission Computed Tomography in Epilepsies
137. Association of central serotonin transporter availability and body mass index in healthy Europeans
138. In vivo type 1 cannabinoid receptor availability in Alzheimer's disease
139. Clinical SPECT and PET for Management of Patients with Epilepsy
140. Patient Safety Considerations for Combined PET/MR Imaging
141. Prospective comparison of [18F]AlF-NOTA-octreotide PET/MRI to [68Ga]Ga-DOTATATE PET/CT in neuroendocrine tumor patients.
142. Longitudinal Synaptic Density PET with 11C‐UCB‐J 6 Months After Ischemic Stroke.
143. Single-word comprehension deficits in the nonfluent variant of primary progressive aphasia
144. On the optimal z-score threshold for SISCOM analysis to localize the ictal onset zone
145. Mixed response on regorafenib treatment for GIST (gastro-intestinal stromal tumor) according to 18F–FDG-PET/CT
146. Lack of endogenous opioid release during sustained visceral pain: A [11C]carfentanil PET study
147. Increased ventral striatal CB1 receptor binding is related to negative symptoms in drug-free patients with schizophrenia
148. Outcome after epilepsy surgery at the University Hospitals Leuven 1998–2012
149. Implementation of the European multicentre database of healthy controls for [123I]FP-CIT SPECT increases diagnostic accuracy in patients with clinically uncertain parkinsonian syndromes
150. Reduction in camera-specific variability in [123I]FP-CIT SPECT outcome measures by image reconstruction optimized for multisite settings: impact on age-dependence of the specific binding ratio in the ENC-DAT database of healthy controls
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.